Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers

Introduction to Immunohistochemistry (IHC) in Thoracic Tumors

  • Context: IHC is an essential tool for classifying pleuropulmonary and mediastinal cancers, aiding therapeutic decisions and prognostic predictions.

  • Objective: Enhance diagnostic accuracy and classification of pleuropulmonary neoplasms using IHC.

  • Data Sources: Literature review, personal practice experience, and research data.

  • Conclusion: Proper selection of IHC panels significantly aids in diagnosing primary pleuropulmonary neoplasms and differentiating them from metastatic tumors.

Advances in IHC Techniques

  • Emergence of Novel Markers:

    • Improved sensitivity and specificity in diagnostics due to new tumor-associated biomarkers.

    • Development of better monoclonal antibodies and staining techniques.

  • WHO Classifications: Introduction of IHC in the 2015 and 2021 WHO classifications of lung cancer emphasizes its importance in routine practice, particularly for poorly differentiated tumors.

Key Applications of IHC for Pleuropulmonary Tumors

  • Differentiation between Adenocarcinoma (ADC) and Squamous Cell Carcinoma (SCC):

    • ADC is more likely to harbor driver genetic alterations than SCC.

    • Distinguishing between ADC and SCC is crucial for therapeutic decisions, necessitating the use of IHC.

  • Commonly Used IHC Markers:

    • For ADC: TTF1, Napsin A, both positive in 85-90% of cases.

    • For SCC: p40, p63, CK5/6. Over 90% positivity in SCC cases.

Detailed Marker Analysis

TTF1 and Napsin A

  • TTF1:

    • Nuclear positivity suggests lung ADC. Monoclonal antibodies 8G7G3/1 (specific for ADC) and SPT24 (more sensitive) are commonly used.

    • Napsin A: Useful secondary marker recommended after TTF1, with some overlap in positivity in other organ ADCs.

  • Challenges with Mucinous ADC:

    • Many cases negative for TTF1/napsin A; role of CK20 and CDX2 in distinguishing sources of mucinous tumors.

IHC in Neuroendocrine Tumors (NETs)

  • Classification of NETs: High-grade small cell lung carcinoma, large cell neuroendocrine carcinoma, and carcinoid tumors.

  • Key IHC Markers: Chromogranin A, synaptophysin, CD56, and recently recognized INSM1.

  • Diagnostic Confirmation: A combination of these markers is recommended for confirming NET diagnoses.

IHC for Undifferentiated and Uncommon Pulmonary Cancers

  • Large Cell Carcinoma (LCC): Diagnosis requires exclusion of other types; negative staining for both ADC and SCC markers is necessary.

  • Sarcomatoid Carcinoma: Requires adequate IHC workup to differentiate from spindle cell tumors.

  • Thoracic SMARCA4-Deficient Undifferentiated Tumor: Highly aggressive, primarily affecting younger patients. Key markers include loss of SMARCA4 and expression of SOX2.

IHC for Differentiation of Primary from Metastatic Lung Carcinomas

  • Importance of Distinction: Identifying metastatic lung tumors requires a panel of markers including TTF1 and napsin A, supplemented by specific organ markers like GATA3 for breast tumors.

  • Common Challenges: Overlapping expression patterns between primary and metastatic cancers, particularly with mucinous adenocarcinomas.

Mesothelioma Diagnosis via IHC

  • Primary Diagnostic Tools: Assessment of morphologic features along with IHC is essential for diagnosing malignant mesothelioma (MM).

  • Key IHC Markers: Calretinin, podoplanin, and loss of BAP1 are critical for differentiating MM from reactive mesothelial proliferations.

  • Differentiation from Metastatic Tumors: A comprehensive marker panel is required to accurately interpret between MM and metastatic carcinomas.

Conclusion

  • Importance of IHC: IHC parameters significantly enhance the diagnostic accuracy for pleuropulmonary and mediastinal tumors, essential for personalized medicine in current clinical practices.

  • Future Directions: Continued development in IHC markers and methodologies will likely improve diagnostic standards.